A phase II clinical study of oral suberoylanilide hydroxamic acid [vorinostat] in patients with relapsed or refractory breast, colorectal and non-small cell lung cancer.
Phase of Trial: Phase II
Latest Information Update: 12 Apr 2017
At a glance
- Drugs Vorinostat (Primary)
- Indications Breast cancer; Colorectal cancer; Non-small cell lung cancer
- Focus Therapeutic Use
- 25 Nov 2005 New trial record.